HOME >> BIOLOGY >> NEWS
Inhibition Of A Novel Gene Involved In Phosphorylating Starch In TransgenicPotato Tubers Leads To The Repression Of Cold Induced Sweetening

ctin are plentifold and not easily obtained.

A further phenotype associated with the reduction of phosphate in the starch is linked to its degradability in different organs of the potato. Initially it was observed that the transgenic potatoes were unable to degrade their starch in leaves even after extremely prolonged (7 days) periods of darkness. The same was later measured in cold-stored potato tubers. The phenomenon of starch degradation and concomittant accumulation of sugars in plant organs induced by low temperatures (cold-induced sweetening) was first described by Mueller-Thurgau, a famous German grapevine breeder, in 1888. Many attempts have been undertaken to circumvent this phenomenon in potato tubers; however, most of them failed. The researchers interpret this observation as a side-effect of the altered starch properties on the starch-degradative machinery present in potato plants. It is hypothesized that the altered starch is not degradable by the enzymes present in potato tubers.

Both of the phenomena observed, the influence on starch phosphorylation and degradation, have a significant impact on plant biotechnology. The high phosphate content of potato starch is an attribute which makes potato starch superior to other commercially available starches. If it was possible to transfer this characteristic to graminaceous and other species, it would open a wide range of novel applications of starch as a renewable resource. In addition, cold sweetening is a severe problem in the potato processing industry as a high sugar content leads to the occurence of the Maillard reaction during frying, which is manifested by the undesired dark staining of potato chips and french fries. Si
'"/>

Contact: Jens Kossmann
Kossmann@Mpimp-Golm.MPG.de
+49-331-9772-784
Max-Planck-Gesellschaft
14-May-1998


Page: 1 2 3 4

Related biology news :

1. Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice
2. Inhibition of insulin-like growth factor receptor-1 as promising anticancer therapeutic
3. Inhibition of Borrelia burgdorferi protein may reduce Lyme disease transmission
4. Competitive Inhibition May Enhance Safety Of Minimally Processed Fruits And Vegetables
5. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
6. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
7. Novel approaches to current cellular therapies continue progress toward disease prevention
8. Novel therapies show promise against myeloid leukemia
9. Novel sensors help clear the air
10. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
11. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis

Post Your Comments:
(Date:6/19/2013)... at the University of Pittsburgh has developed antibacterial ... that could be potential treatments for drug-resistant bacterial ... new agents are quite small, making them inexpensive ... in the June 2013 issue of the journal ... first of many probable applications will likely be ...
(Date:6/19/2013)... June 19, 2013 A decade-long JDRF-funded study ... Helmholtz Zentrum Mnchen, Germany, is providing a deeper ... risk of developing type 1 diabetes (T1D), highlighting ... for the disease. The study, "Seroconversion to Multiple ... in Children," was published today in The ...
(Date:6/19/2013)... how pearls form into the most perfectly spherical large ... are proposing in a new study. It appears in ... Laureate Irving Langmuir. , Julyan Cartwright, Antonio G. Checa ... and highly prized pearls have perhaps the most perfectly ... nature that are visible without a microscope. Pearls develop ...
Breaking Biology News(10 mins):HIV-derived antibacterial shows promise against drug-resistant bacteria 2New data on islet autoantibodies in young children defines early type 1 diabetes development 2
(Date:6/19/2013)... BREA, Calif. , June 19, 2013  Continuing ... of myocardial infarction (MI), Beckman Coulter , Inc. ... clearance of its new Access AccuTnI+3 troponin I assay ... "Clinicians have depended on Beckman Coulter,s ... the new AccuTnI+3 assay has the proven performance to ...
(Date:6/19/2013)... Biotechnology industry pioneer Amgen (NASDAQ: ... BlackLine Systems  and enterprise application software leader ... webinar next week entitled "No Account Left Behind!  ... to Help Keep Its Account Reconciliations in Good Shape ... The webinar, geared at finance, accounting, audit and compliance ...
(Date:6/19/2013)... Applied Rigaku Technologies, Inc. is pleased ... measurement of sulfur in ultra-low sulfur diesel (ULSD) using ... EDXRF analyzer . The analysis detailed in Rigaku Application ... This International Standard specifies an energy dispersive X-ray ... content in automotive gasoline. , Regulations around the world ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Tabletop SEMs ... size SEMs but have limited performance and capability such ... Full size SEMs would normally provide better imaging performance ... to operate and have a higher cost of maintenance. ... the gap between these two types of SEM product, ...
Breaking Biology Technology:Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4Rigaku Publishes New Application Note for Analysis of ULSD Per ISO 13032 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 2Nanounity Introduces the Pemtron Range of Compact Scanning Electron Microscopes 3
Cached News: